Genomind®, a unique personalized medicine platform that brings innovation to healthcare around the world, is pleased to present this summary of the genes behind our pharmacogenetic products. Our products are used to assist clinical decision-making when prescribing medication across multiple conditions. These products include:
1) The Genomind Pharmacogenetic Report:
- Genomind Express Report: A concise summary of medications to avoid, along with suggested alternatives, based on the patient’s unique gene-drug interaction profile and published PGx guidelines.
- Genomind NeuroPsych Report: A comprehensive report with five sections analyzing 26 genes, offering insights into 130+ neuropsychiatric medications.
- Genomind Diagnosis Report: Visual representations of genetic results organized by clinical diagnosis, designed for fast interpretation when time is limited.
- Genomind Patient Report: A simplified report designed for patients, offering an easy-to-understand summary of genetic insights and medication recommendations to discuss with their healthcare provider.
2) GenMedProTM: an interactive clinical decision support software that identifies drug-drug interactions (DDI) and drug-gene interactions (DGI). The software provides published PGx treatment guidelines and an alternative medication feature.
Testing for our products is a simple, non-invasive buccal test (cheek swab) that can be administered quickly in a clinician’s office or by the patient at home. A complimentary consultation with experts in the field of pharmacogenetics is available to the clinician with each patient report.
